![]() |
Name |
Norlichexanthone
|
Molecular Formula | C14H10O5 | |
IUPAC Name* |
1,3,6-trihydroxy-8-methylxanthen-9-one
|
|
SMILES |
CC1=CC(=CC2=C1C(=O)C3=C(C=C(C=C3O2)O)O)O
|
|
InChI |
InChI=1S/C14H10O5/c1-6-2-7(15)4-10-12(6)14(18)13-9(17)3-8(16)5-11(13)19-10/h2-5,15-17H,1H3
|
|
InChIKey |
AQZHBCDRWFMXIN-UHFFFAOYSA-N
|
|
Synonyms |
Norlichexanthone; 20716-98-7; 1,3,6-Trihydroxy-8-methyl-9H-xanthen-9-one; 9H-xanthen-9-one, 1,3,6-trihydroxy-8-methyl-; 1,3,6-trihydroxy-8-methylxanthen-9-one; CHEMBL466154; CHEBI:7632; 1,3,6-trihydroxy-8-methyl-xanthen-9-one; 3,6,8-Trihydroxy-1-methylxanthone; Fusarindin; AC1NQYTV; Fusarindin; Xanthen-9-one, 1,3,6-trihydroxy-8-methyl-; ACon0_000599; ACon1_001113; DTXSID20174777; GLXC-17037; 1,3,6-trihydroxy-8-methylxanthone; ZINC5765089; BDBM50350423; AKOS000365318; BS-1325; NCGC00169665-01; 1,3,6-Trihydroxy-8-methyl-9H-xanthen-9-one #; BRD-K97951054-001-01-6; Q27107546; NCGC00169665-03!1,3,6-trihydroxy-8-methylxanthen-9-one
|
|
CAS | 20716-98-7 | |
PubChem CID | 5281657 | |
ChEMBL ID | CHEMBL466154 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 258.23 | ALogp: | 2.8 |
HBD: | 3 | HBA: | 5 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 87.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 19 | QED Weighted: | 0.539 |
Caco-2 Permeability: | -4.974 | MDCK Permeability: | 0.00000683 |
Pgp-inhibitor: | 0.003 | Pgp-substrate: | 0.868 |
Human Intestinal Absorption (HIA): | 0.015 | 20% Bioavailability (F20%): | 0.61 |
30% Bioavailability (F30%): | 0.994 |
Blood-Brain-Barrier Penetration (BBB): | 0.018 | Plasma Protein Binding (PPB): | 94.01% |
Volume Distribution (VD): | 0.776 | Fu: | 8.14% |
CYP1A2-inhibitor: | 0.983 | CYP1A2-substrate: | 0.814 |
CYP2C19-inhibitor: | 0.198 | CYP2C19-substrate: | 0.056 |
CYP2C9-inhibitor: | 0.614 | CYP2C9-substrate: | 0.94 |
CYP2D6-inhibitor: | 0.774 | CYP2D6-substrate: | 0.654 |
CYP3A4-inhibitor: | 0.475 | CYP3A4-substrate: | 0.094 |
Clearance (CL): | 6.9 | Half-life (T1/2): | 0.877 |
hERG Blockers: | 0.018 | Human Hepatotoxicity (H-HT): | 0.063 |
Drug-inuced Liver Injury (DILI): | 0.893 | AMES Toxicity: | 0.421 |
Rat Oral Acute Toxicity: | 0.056 | Maximum Recommended Daily Dose: | 0.925 |
Skin Sensitization: | 0.919 | Carcinogencity: | 0.031 |
Eye Corrosion: | 0.345 | Eye Irritation: | 0.971 |
Respiratory Toxicity: | 0.3 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001750 | ![]() |
0.754 | D0K8KX | ![]() |
0.493 | ||
ENC001652 | ![]() |
0.733 | D04AIT | ![]() |
0.486 | ||
ENC002024 | ![]() |
0.683 | D07MGA | ![]() |
0.345 | ||
ENC002405 | ![]() |
0.678 | D07EXH | ![]() |
0.333 | ||
ENC004883 | ![]() |
0.672 | D06GCK | ![]() |
0.315 | ||
ENC004887 | ![]() |
0.672 | D0FA2O | ![]() |
0.269 | ||
ENC002018 | ![]() |
0.656 | D0AZ8C | ![]() |
0.261 | ||
ENC005648 | ![]() |
0.603 | D02UFG | ![]() |
0.260 | ||
ENC002462 | ![]() |
0.600 | D04XEG | ![]() |
0.256 | ||
ENC005649 | ![]() |
0.580 | D0M8RC | ![]() |
0.253 |